HCPCS Level II Q5 codes
78 active HCPCS Level II codes beginning Q5, from Q5001 to Q5171. Part of the full HCPCS Level II index.
- Q5001Hospice or home hlth in home
- Q5002Hospice/home hlth in asst lv
- Q5003Hospice in lt/non-skilled nf
- Q5004Hospice in snf
- Q5005Hospice, inpatient hospital
- Q5006Hospice in hospice facility
- Q5007Hospice in ltch
- Q5008Hospice in inpatient psych
- Q5009Hospice/home hlth, place nos
- Q5010Hospice home care in hospice
- Q5098Inj ustekinumab-srlf, 1 mg
- Q5099Inj ustekinumab-stba, 1 mg
- Q5100Inj ustekinumab-kfce, 1 mg
- Q5101Injection, zarxio
- Q5103Injection, inflectra
- Q5104Injection, renflexis
- Q5105Inj retacrit esrd on dialysi
- Q5106Inj retacrit non-esrd use
- Q5107Inj mvasi 10 mg
- Q5108Injection, fulphila
- Q5110Nivestym
- Q5111Injection, udenyca 0.5 mg
- Q5112Inj ontruzant 10 mg
- Q5113Inj herzuma 10 mg
- Q5114Inj ogivri 10 mg
- Q5115Inj truxima 10 mg
- Q5116Inj., trazimera, 10 mg
- Q5117Inj., kanjinti, 10 mg
- Q5118Inj., zirabev, 10 mg
- Q5119Inj ruxience, 10 mg
- Q5120Inj pegfilgrastim-bmez 0.5mg
- Q5121Inj. avsola, 10 mg
- Q5122Inj, nyvepria
- Q5123Inj. riabni, 10 mg
- Q5124Inj. byooviz, 0.1 mg
- Q5125Inj, releuko 1 mcg
- Q5126Inj alymsys 10 mg
- Q5127Inj, stimufend, 0.5 mg
- Q5128Inj, cimerli, 0.1 mg
- Q5129Inj, vegzelma, 10 mg
- Q5130Inj, fylnetra, 0.5 mg
- Q5133Inj, tofidence, 1 mg
- Q5134Inj, tyruko, 1 mg
- Q5135Inj, tyenne, 1 mg
- Q5136Inj. denosumab-bbdz, 1 mg
- Q5137Inj, wezlana, sub cu, 1 mg
- Q5138Inj, wezlana, iv, 1 mg
- Q5140Inj adalimumab-fkjp, 1 mg
- Q5141Inj adalimumab-aaty, 1 mg
- Q5142Inj adalimumab-ryvk, 1 mg
- Q5143Inj adalimumab-adbm, 1 mg
- Q5144Inj, idacio, 1 mg
- Q5145Inj, abrilada, 1 mg
- Q5146Inj, hercessi, 10 mg
- Q5147Inj, aflibercept-ayyh, 1 mg
- Q5148Inj, nyposi 1 mcg
- Q5149Inj, aflibercept-abzv, 1 mg
- Q5150Inj, aflibercept-mrbb, 1 mg
- Q5151Inj, eculizumab-aagh, 2 mg
- Q5152Inj, eculizumab-aeeb, 2 mg
- Q5153Inj, aflibercept-yszy, 1 mg
- Q5154Inj, omlyclo, 5 mg
- Q5155Inj, aflibercept-jbvf, 1 mg
- Q5156Inj, tocilizumab-anoh, 1 mg
- Q5157Inj, denosumab-bmwo, 1 mg
- Q5158Inj, denosumab-bnht, 1 mg
- Q5159Inj, denosumab-dssb, 1 mg
- Q5160Inj, jobevne, 10 mg
- Q5161Inj, denosumab-kyqq, 1 mg
- Q5162Inj, denosumab-nxxp, 1 mg
- Q5164Ustekinumab-hmny, 1 mg
- Q5165Inj, denosumab-mobz, 1 mg
- Q5166Inj, denosumab-desu, 1 mg
- Q5167Inj, denosumab-qbde, 1 mg
- Q5168Inj. nufymco, 0.1 mg
- Q5169Inj, armlupeg, 0.5 mg
- Q5170Inj, aflibercept-boav, 1 mg
- Q5171Inj, den (boncres), bio, 1mg
Source
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.